Researchers examined data on pediatric patients with ESBL-producing Enterobacteriaceae infections from 2008 to 2011. They found 60 percent of the infections occurred in the intensive care unit and 30 percent occurred in outpatient settings. The majority of them, 77 percent, were resistant to at least three antibiotic classes.
Additionally, researchers found ESBL infections were 5.7 times more likely to cause gastrointestinal comorbidities and 3.3 times more likely to cause neurological comorbidities than non-ESBL infection controls.
ESBL infections reoccurred in 17 percent of patients, and both ESBL and controls experienced a 7 percent mortality rate.
More Articles on Antimicrobials:
Researchers Develop Light-Activated Antibacterial Surface That Still Works in Dark
Cefepime, Carbapenems Equally Effective in Treating Enterobacter
Children Experiencing More Resistant Bacterial Infections
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
